Osteoarthritis Treatment Industry Trends and Forecast

Osteoarthritis Treatment Market - Industry

Trends & Forecast

Market Overview:

Data Bridge Market Research analyses that the osteoarthritis treatment market was valued at USD 6,214.06 million in 2021 and is expected to reach USD 10,100.30 million by 2029, registering a CAGR of 6.26% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Download

https://www.databridgemarketresearch.com/request-a-

Market Segmentation:

Global Osteoarthritis Treatment Market, By Anatomy (Hand Osteoarthritis, Knee

Osteoarthritis, Hip Osteoarthritis, Small Joint Osteoarthritis), Drug Type (Prescription Drugs, Over-the-Counter Drugs), Treatment Type (Medication, Surgery, Therapy), Route of Administration (Oral, Parenteral, Others), Dosage Form (Tablets, Injections, Others), Diagnosis (Imaging Tests, Joint Fluid Analysis, Blood Tests, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

Major Key Players

Some of the major players operating in this market

are : F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Zydus Cadila (India), Boehringer Ingelheim International

GmbH. (Germany), Apotex Inc. (Canada), AstraZeneca (U.K.), Horizon Therapeutics

PLC (Ireland), Johnson & Johnson Private Limited (U.S.), Bayer AG (Germany), Perrigo Company plc (Ireland), Tolmar Pharmaceuticals, Inc. (U.S.), Reckitt

Benckiser Group PLC (U.K.), Sun Pharmaceutical Industries Ltd. (India), Assertio Therapeutics, Inc. (U.S.), DAIICHI SANKYO COMPANY, LIMITED (Japan)

Read More About this report @

https://www.databridgemarketresearch.com/reports/global-osteoarthritis-treatmentmarket#:~:text=Data%20Bridge%20Market%20Research%20analyses,period%20of%2020 22%20to%202029.

Market Drivers:

The rising prevalence of osteoarthritis is estimated to enhance the osteoarthritis treatment market's growth. Injury, obesity, and a variety of other factors contribute to osteoarthritis. The damaged bodily part has severe joint pain and stiffness. Swelling of joints, tingling in the legs and limbs, and a reduction in range of motion are all indications of osteoarthritis. As per a study published in the Lancet Journal in November 2020, osteoarthritis affected about 7% of the global population, or more than 500 million people, in 2019, with women disproportionately affected. The number of people affected by osteoarthritis globally increased by 48 percent from 1990 to 2019, and osteoarthritis was the 15th leading cause of years lived with disability (YLDs) in 2019.

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:- corporatesales@databridgemarketresearch.com